Banner Lauren, Joffe Daniel, Lee Emily, Porcu Pierluigi, Nikbakht Neda
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, United States.
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States.
Front Med (Lausanne). 2023 Apr 6;10:1110511. doi: 10.3389/fmed.2023.1110511. eCollection 2023.
The increased incidence of cutaneous melanoma (CM) and Merkel cell carcinoma (MCC) in patients with hematologic malignancies (HM) is well established. While the risk of CM has been assessed in some subtypes of HM including cutaneous T-cell lymphoma, the incidence in patients with primary cutaneous B-cell lymphoma (PCBCL) has not been interrogated.
Here we evaluated the standardized incidence ratio (SIR) of CM and MCC in 5,179 PCBCL patients compared to approximately 1.5 billion individuals in the general population using the Surveillance, Epidemiology and End Results (SEER) database. Among patients with PCBCL, we identified subgroups that were at increased risk for CM or MCC as a second primary cancer.
We found 36 cases of CM in the PCBCL cohort (SIR, 1.35; 95% CI, 0.94-1.86), among which SIR was significantly elevated for non-Hispanic White patients compared to the general population (SIR, 1.48; 95% CI, 1.03-2.06). Males had a significantly increased risk of developing CM after a diagnosis of PCBCL (SIR, 1.60; 95% CI, 1.10-2.26). We found that males in the age group of 50-59 were at increased risk for CM development (SIR, 3.02; 95% CI, 1.11-6.58). Males were at increased risk of CM 1-5 years after PCBCL diagnosis (SIR, 2.06; 95% CI, 1.18-3.34). Patients were at greater risk of developing MCC within 1 year of diagnosis of PCBCL (SIR, 23.60; 95% CI, 2.86-85.27), particularly in patients who were over the age of 80 (SIR, 46.50; 95% CI, 5.63-167.96). Males aged 60-69 with PCBCL, subtype marginal zone, were also at increased risk for MCC (SIR, 42.71; 95% CI, 1.08-237.99).
There is an increased incidence of CM in White, middle-aged males within 5 years of diagnosis of PCBCL and an increased risk of MCC in elderly patients within 1 year of PCBCL diagnosis. These data suggest that certain subgroups of patients with PCBCL may require more rigid surveillance for CM and MCC.
血液系统恶性肿瘤(HM)患者中皮肤黑色素瘤(CM)和默克尔细胞癌(MCC)的发病率增加已得到充分证实。虽然已在包括皮肤T细胞淋巴瘤在内的某些HM亚型中评估了CM的风险,但原发性皮肤B细胞淋巴瘤(PCBCL)患者的发病率尚未得到研究。
在此,我们使用监测、流行病学和最终结果(SEER)数据库,评估了5179例PCBCL患者中CM和MCC的标准化发病比(SIR),并与普通人群中约15亿人进行了比较。在PCBCL患者中,我们确定了作为第二原发性癌症发生CM或MCC风险增加的亚组。
我们在PCBCL队列中发现了36例CM(SIR,1.35;95%CI,0.94-1.86),其中非西班牙裔白人患者的SIR与普通人群相比显著升高(SIR,1.48;95%CI,1.03-2.06)。男性在诊断PCBCL后发生CM的风险显著增加(SIR,1.60;95%CI,1.10-2.26)。我们发现50-59岁年龄组的男性发生CM的风险增加(SIR,3.02;95%CI,1.11-6.58)。男性在PCBCL诊断后1-5年发生CM的风险增加(SIR,2.06;95%CI,1.18-3.34)。患者在PCBCL诊断后1年内发生MCC的风险更高(SIR,23.60;95%CI,2.86-85.27),特别是80岁以上的患者(SIR,46.50;95%CI,5.63-167.96)。PCBCL亚型边缘区的60-69岁男性发生MCC的风险也增加(SIR,42.71;95%CI,1.08-237.99)。
在PCBCL诊断后5年内,白人中年男性CM发病率增加,在PCBCL诊断后1年内,老年患者MCC风险增加。这些数据表明,PCBCL患者的某些亚组可能需要对CM和MCC进行更严格的监测。